NervMyo Therapeutics has created a long‑acting injectable platform that delivers small proteins directly to injured nerves. Their lead product uses a safe delivery system to provide sustained, local release of the FDA‑approved biologic insulin‑like growth factor‑1 (IGF‑1), promoting nerve regeneration and preventing muscle wasting. Efficacy has been shown in rodent and non‑human primate models, positioning the therapy for upcoming safety studies and clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Peripheral nerve injuries often lead to incomplete nerve regeneration and subsequent muscle wasting because therapeutic proteins like insulin‑like growth factor‑1 (IGF‑1) cannot be delivered locally in a sustained manner. Existing delivery methods require repeated injections or systemic administration, which are inefficient and increase risk of side effects.
Solution
NervMyo Therapeutics has engineered a long‑acting injectable platform that encapsulates small therapeutic proteins for targeted, localized release at the injury site. The system uses a safe, biocompatible depot formulation to continuously release FDA‑approved IGF‑1 directly onto damaged nerves, supporting axonal regrowth and preserving muscle mass. Preclinical studies in rodents and non‑human primates demonstrated robust functional recovery and reduced muscle atrophy with a single injection. The platform is designed to be compatible with other small protein biologics, enabling a pipeline of nerve‑repair therapies. By providing sustained, site‑specific exposure, the technology aims to improve outcomes while minimizing the need for repeated dosing.
Target Audience
Primary customers are pharmaceutical and biotech companies developing peripheral nerve injury treatments, as well as clinical researchers and specialty hospitals seeking advanced regenerative therapies for nerve trauma.
Features
- Injectable depot formulation that releases IGF‑1 over an extended period (weeks to months) at the nerve injury site
- Biocompatible, FDA‑compatible carrier matrix ensuring safety and minimal local inflammation
- Localized delivery minimizes systemic exposure and associated side effects
- Platform adaptable to other small protein therapeutics for peripheral nerve regeneration
- Demonstrated efficacy in both rodent and non‑human primate models, supporting translational potential